Lawsuit Deadline Nears for Gossamer Bio Investors Alleging Concealed Placebo Risk in Failed Drug Trial
GOSS sits 31% above its 52-week low of $0.163.
Summary
A law firm issued a deadline alert for investors to join a class-action lawsuit against Gossamer Bio, with a lead plaintiff deadline of June 1, 2026. The lawsuit alleges executives concealed critical information about placebo risk and trial design issues in the Phase 3 PROSERA study, which failed to meet its primary endpoint. This follows the company's prior disclosures in its 10-K and 10-Q filings regarding the class action. The detailed allegations of misconduct add to the severe financial distress, Nasdaq delisting notice, and ongoing distressed debt exchange already facing Gossamer Bio.
At the time of this announcement, GOSS was trading at $0.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.2M. The 52-week trading range was $0.16 to $3.87. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.